Whittier Street Health Center to Honor Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden at Its 2024 Annual Gala

Whittier’s Annual Roast to Toast Fundraiser on April 3rd, 2024 Will Support Health and Social Services for Boston’s Most Vulnerable Residents

BOSTON, MA / ACCESSWIRE / March 11, 2024 / Whittier’s 2024 “Toast of Jeffrey Leiden” will continue the health center’s long tradition of shining a light on Boston’s standout business leaders and philanthropists while raising critical funds to provide high-quality medical care and social services to patients regardless of their ability to pay for services.

Caricature of Dr. Jeffrey Leiden
Toast of Jeffrey Leiden

WCVB Channel 5 “CityLine” host and executive producer Karen Holmes Ward will emcee the event, which will feature live entertainment by Anima. Members of the public are invited to attend.

When: Wednesday, April 3, 2024, 5:30-9:00 p.m.
Where: Hilton Boston Park Plaza Hotel, 50 Park Plaza, Boston, MA 02116
Click here to purchase a ticket: https://www.wshc.org/event/toast-of-jeffrey-leiden-m-d-ph-d-executive-chairman-vertex/

Speakers include John Fish, Chairman & CEO, Suffolk Construction, Joe Nolan, Chairman, President & CEO, Eversource Energy, Dr. Reshma Kewalramani, President, Vertex Pharmaceuticals, Dr. Betsy Nabel and Dr. Gary Nabel of ModeX Therapeutics, Dr. Joan Reede, Dean of for Diversity and Community Partnerships, Harvard Medical School, Paul Burton, Journalist, Channel 4 (Boston), Former Congressman Joe Kennedy, and Dr. Sangeeta N. Bhatia, Koch Institute for Integrative Cancer Research.

“Dr. Leiden has been a staunch supporter of Whittier and is one of our most caring and passionate health equity champions,” said Frederica M. Williams, Whittier Street Health Center’s president and CEO. “He understands and cares deeply about the serious health and social inequities that exist in Boston.”

“We’re excited to celebrate Jeff as a compassionate scientist, physician and corporate leader who has a long record as a relentless champion for health equity. And we thank Vertex Pharmaceuticals and our event sponsors for strengthening Whittier’s ability to ensure greater access to high-quality and culturally sensitive health care and social services by implementing innovative programs and services that promote better health and well-being to the residents of Roxbury, the South End, Dorchester, Mattapan, Jamaica Plain and surrounding neighborhoods,” Williams said.

Dr. Leiden currently serves as Executive Chairman of Vertex Pharmaceuticals and was the Chief Executive Officer and President from 2012 through to March 2020. During his tenure as CEO, Dr. Leiden established a signature program at Vertex to enhance STEAM education among students in Vertex’s local communities, including an on-site Learning Lab, mentorship programs, internships and college scholarships.

Contact Information

Press Office
Media and Communications Office
info@wshc.org
617-989-3221

President’s Office
President & CEO
events@wshc.org
617-989-3221

SOURCE: Whittier Street Health Center

View the original press release on newswire.com.

Staff

Recent Posts

Rare Element Resources Announces Appointment of Ken Mushinski as President and Chief Executive Officer

LITTLETON, Colo.--(BUSINESS WIRE)--Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to…

37 mins ago

Red Light Holland Announces Happy Caps Mushroom Home Grow Kits Now Available in Over 270 Retail Stores Across Canada

Significant increase in number of points of sale (100%) for Happy Caps Mushroom Home Grow…

38 mins ago

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the…

39 mins ago

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

PharmAla now first company to supply both MDMA and Psilocybin into the Australian MarketVANCOUVER, British…

39 mins ago

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024SCOTTSDALE, Ariz., March 18,…

39 mins ago